Project Grant HT94252510557

The National Institute on Deafness and Other Communication Disorders (NIDCD) awarded a $305,628 Project Grant under the CFDA 93.173 Research Related to Deafness and Communication Disorders program to Echogenesis Therapeutics Inc. The grant will fund the development of a cell-type-specific gene therapy approach to treat congenital hearing loss caused by mutations in the TOMT gene. Specifically, the project aims to: 1) determine effective dosages for hearing restoration, 2) establish the optimal...

This Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD), under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), provides $581,105 to Creighton University to develop natural-based therapies for treating hearing loss caused by aminoglycoside antibiotics. The key focus is on designing, synthesizing, and testing piperlongumine derivatives that can better target the TRPV1 channel to protect hair cells and synapses...

The National Institute on Deafness and Other Communication Disorders (NIDCD) awarded a $275,371 Project Grant (CFDA 93.173) to Auricle Health Inc. to develop an extracochlear device to restore hearing for patients with sensorineural hearing loss (SNHL). The funding will support refinement of the electrode design, demonstration of electrical stimulation of the cochlear nerve in animal models, and evaluation of the long-term safety and durability of the implant. This project aims to create a...

This $3,314,560 Cooperative Agreement award, funded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), aims to develop CRISPR-Cas-based gene editing therapies for two types of dominant genetic hearing loss, DFNA41 and DFNA2. The award recipient, Massachusetts Eye and Ear Infirmary, will conduct IND-enabling studies, including evaluating off-target effects, efficacy in animal models, and safety in non-human primates. The...

The National Institute on Deafness and Other Communication Disorders (NIDCD) awarded a $498,000 Project Grant under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to the University of Pittsburgh. The project aims to develop an ex-vivo porcine round window membrane (RWM) model to evaluate the transport of nanovesicles, including extracellular vesicles (exosomes), as a method for non-surgical delivery of therapeutics to the inner ear to treat and prevent hearing...

The National Institute on Deafness and Other Communication Disorders (NIDCD), under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), awarded a $306,073 Project Grant to Iotamotion, Inc. to develop a navigation-based cochlear implant insertion system that optimizes trajectory while enabling slow and consistent electrode array insertions. The goal is to improve short and long-term hearing outcomes for cochlear implant patients by enhancing structural preservation...

This $659,164 Project Grant awarded by the National Institute on Deafness and Other Communication Disorders (NIDCD), under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), aims to identify pharmacological modulators, endogenous ligands, and binding partners for the orphan G protein-coupled receptor GPR156. The grant, awarded to the University of Rochester, will leverage innovative cell-based assays and proximity-mediated labeling technologies to discover new...

This federal Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD), under CFDA program 93.173 "Research Related to Deafness and Communication Disorders", provides $265,410 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) for a research project titled "Defining the Role of MET Components in Vestibular Hair Cell Maturation and Gene Therapy Responsiveness". The project aims to better...

This Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD), under the federal Research Related to Deafness and Communication Disorders program (CFDA 93.173), provides $115,158 to the University of Virginia to investigate the role of phosphatidylserine (PS) signaling in pruning spiral ganglion neurons (SGNs) during cochlear development. The central hypothesis is that PS presentation marks inactive outer hair cell-SGN connections for removal by...

The National Institutes of Health's National Eye Institute awarded Greffex Inc. a $902,455 Project Grant under the Vision Research program (CFDA 93.867) to develop an Usher gene therapy. Greffex will leverage its fully deleted adenoviral vector platform, which can accommodate payloads up to 33kb, to deliver a full-length Usher Syndrome Type 2A coding cDNA to photoreceptors. This aims to establish an efficient gene transfer method to treat Usher Syndrome Type 2, the leading genetic cause of...